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Abstract
Background
Women with diabetes have a worse survival after breast cancer diagnosis compared to
women without diabetes. This may be due to a different etiological profile, leading to the
development of more aggressive breast cancer subtypes. Our aim was to investigate
whether insulin and non-insulin treated women with diabetes develop specific clinicopatho-
logical breast cancer subtypes compared to women without diabetes.
Methods and Findings
This cross-sectional study included randomly selected patients with invasive breast cancer
diagnosed in 2000–2010. Stratified by age at breast cancer diagnosis (50 and >50 years),
women with diabetes were 2:1 frequency-matched on year of birth and age at breast cancer
diagnosis (both in 10-year categories) to women without diabetes, to select ~300 patients
with tumor tissue available. Tumor MicroArrays were stained by immunohistochemistry for
estrogen and progesterone receptor (ER, PR), HER2, Ki67, CK5/6, CK14, and p63. A
pathologist scored all stains and revised morphology and grade. Associations between dia-
betes/insulin treatment and clinicopathological subtypes were analyzed using multivariable
logistic regression. Morphology and grade were not significantly different between women
with diabetes (n = 211) and women without diabetes (n = 101), irrespective of menopausal
status. Premenopausal women with diabetes tended to have more often PR-negative (OR =
2.44(95%CI:1.07–5.55)), HER2-negative (OR = 2.84(95%CI:1.11–7.22)), and basal-like
(OR = 3.14(95%CI:1.03–9.60) tumors than the women without diabetes, with non-signifi-
cantly increased frequencies of ER-negative (OR = 2.48(95%CI:0.95–6.45)) and triple neg-
ative (OR = 2.60(95%CI:0.88–7.67) tumors. After adjustment for age and BMI, the
associations remained similar in size but less significant. We observed no evidence for
associations of clinicopathological subtypes with diabetes in postmenopausal women, or
with insulin treatment in general.
PLOS ONE | DOI:10.1371/journal.pone.0170084 January 11, 2017 1 / 16
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPENACCESS
Citation: Bronsveld HK, Jensen V, Vahl P, De Bruin
ML, Cornelissen S, Sanders J, et al. (2017)
Diabetes and Breast Cancer Subtypes. PLoS ONE
12(1): e0170084. doi:10.1371/journal.
pone.0170084
Editor: Aamir Ahmad, University of South Alabama
Mitchell Cancer Institute, UNITED STATES
Received: August 31, 2016
Accepted: December 28, 2016
Published: January 11, 2017
Copyright:© 2017 Bronsveld et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: The raw data cannot
be shared due to restrictions as described in
Danish Law (Persondataloven: https://www.
retsinformation.dk/forms/r0710.aspx?id=828). The
anonymized data can only be analyzed on the
server of Statistics Denmark. Data requests should
follow the official procedure of statistics Denmark;
see http://www.dst.dk/en/TilSalg/Forskningsservice
and needs approval from Statistics Denmark.
Funding: The research leading to the results of this
study has received funding from the European
Community’s Seventh Framework Programme
Conclusions
We found no compelling evidence that women with diabetes, treated with or without insulin,
develop different breast cancer subtypes than women without diabetes. However, premeno-
pausal women with diabetes tended to develop breast tumors that do not express hormonal
receptors, which are typically associated with poor prognosis.
Introduction
Diabetes mellitus and breast cancer are chronic diseases with increasing incidence in many
countries [1,2]. Recent estimates indicate that diabetes prevalence is 9.1% among women in
Europe [1] and life-time risk for breast cancer is 9.7% [3]. Most patients with diabetes (~90%)
have type 2 disease, characterized by reduced insulin secretion and insulin resistance with
diagnosis in late adulthood, while patients with type 1 diabetes are insulin deficient [4].
Several studies have investigated whether diabetes and/or insulin (analogue) treatment
increase breast cancer risk [5–10] or affect prognosis [11–18], because of their potential impact
on tumor progression through e.g. the insulin-like growth receptor pathway [5,19]. Women
with diabetes have a 15–20% increased risk of breast cancer compared to women without dia-
betes [6–9], but no impact of insulin analogue treatment has been shown [5]. Breast cancer in
women with diabetes is often diagnosed at an advanced stage compared to women without
diabetes [13,14,20–22]. Moreover, overall mortality after breast cancer diagnosis has been
shown to be 30–60% higher in women with diabetes compared to women without diabetes
[11–16], even after adjustment for tumor stage [13,14,16]. However, studies that investigated
the association between breast cancer-specific mortality and diabetes show inconsistent results
[11,23–27].
Diabetes itself might have a direct effect on breast cancer prognosis due to physiological
effects of hyperglycemia, or hyperinsulinemia, which is a hallmark of insulin resistance com-
monly observed in patients with type 2 diabetes [28,29]. It has been shown that cancer-specific
survival was decreased for women with abnormal glycemic status [25,27] and that fasting insu-
lin levels are associated with worse outcome (distant recurrence and death), independent of
Body Mass Index (BMI) [30]. However, diabetes itself and its complications may also increase
risk of overall mortality [4] and shared cancer-promoting factors in patients with diabetes,
such as obesity and a sedentary lifestyle, increases also the risk of death from competing causes
(metabolic/cardiovascular diseases).
Another reason for the worse breast cancer survival may be that women with diabetes
develop a more aggressive or less treatment-responsive tumor subtype. It has already been
shown that hormone-related breast cancer and diabetes risk factors, such as obesity, are associ-
ated with the development of ER-negative breast cancer subtypes [31,32]. Insulin interacts
with estrogens; there is experimental support that insulin may enhance estrogen production,
stimulating the development of ER-positive breast cancer [19]. Furthermore, the promotion of
tumor cell growth upon insulin exposure may differ by breast cancer subtype; we know from
in vitro studies that mitogenic potential of insulins depends on the type of breast cancer cell
line [5,33]. Although breast cancer subtypes have been extensively studied in the general popu-
lation [31], few studies have assessed breast cancer subtypes in women with diabetes.
The aim of this study is to determine whether breast cancer patients with diabetes have a
specific clinicopathological tumor subtype compared to those without diabetes, and whether
the use of insulin is related to this.
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Methods
The study protocol was approved by the Science Ethics Committee of the Region Midtjylland
in Denmark. The Science Ethics Committee of the Region Midtjylland in Denmark approved
that informed consent for this study was not obtained; however, all women had the possibility
to opt-out from research through the nation-wide registry. Tumor tissue of the women had
been collected for diagnostic or therapeutic purposes around the time of breast cancer diagno-
sis. This tissue is stored in biobanks and may be used for research (‘secondary use’) as long as
coded and anonymous to the researcher. No tissue was used against the will of the patients
(women who opt-out with regard to tissue use for future scientific purposes were excluded
(http://sundhedsdatastyrelsen.dk/da/registre-og-services/vaevsanvendelsesregisteret); no risk
was posed to the women as the tissue had already been removed; and tumor tissue and data
were anonymous for the researcher.
Study design and patient selection
The study population consists of Caucasian women with and without diabetes, diagnosed with
primary breast cancer between 2000 and 2010. The breast cancer patients were selected from a
previously established nation-wide hospital-based cohort, by the Danish Breast Cancer Coop-
erative Group (DBCG) [34]. This cohort was linked to the National Patient Register in Den-
mark to identify women with and without diabetes, covering the years since 1977. In total,
43,701 women were diagnosed with incident breast cancer in 2000–2010 in the DBCG, of
whom 3,047 had diabetes (7.0%). We used a cross-sectional study design with a randomly
selected target population of 300 breast cancer patients. The selected women included breast
cancer patients with diabetes (exposed) and without diabetes (non-exposed) sampled as fol-
lows: a random sample of women with diabetes in strata of age50 and>50 years (1:1) at
breast cancer diagnosis (stratification by age to increase the number of young women) fre-
quency matched with women without diabetes from the same database (1:2) by year of birth
and age at diagnosis (both in 10-year categories) (Fig 1). Twice as many women with diabetes
were included as women without diabetes to allow analyses by insulin treatment. Patients with
a history of other cancers, non-invasive or metastasized breast cancer, those treated with neo-
adjuvant therapy, patients with diabetes diagnosed1 year prior to their breast cancer diagno-
sis, and patients with no or insufficient tumor tissue were excluded.
Data collection
Age, menopausal status, year of breast cancer diagnosis and information on tumor and tumor
treatment were obtained from the DBCG databank and the pathology register of the women.
Only age, year of breast cancer diagnosis, and diabetes status were available at the time of
patient identification. Diabetes status, diabetes type (1 or 2), and age at diabetes diagnosis, as
well as data on socioeconomic status were collected by linkage with the National Patient Regis-
ter (which included all medical diagnoses from 1977 onwards) in Denmark. Data on medica-
tion use, available from 1995 onwards, was obtained by linkage with the Danish Register of
Medicinal Products Statistics. All linkages were done using codes which render the data anon-
ymous to the researchers who do not have direct access to these source databases. Women
were defined as oral contraceptive or hormone replacement users if at least 2 prescriptions of
the drug were prescribed cumulatively in the period up to one year prior to breast cancer diag-
nosis. Additional information on height, weight, Body Mass Index (BMI), smoking, alcohol
use, and HbA1C levels (measure of average glucose levels) prior to breast cancer diagnosis
were retrieved from electronic patient files and anonymized before inclusion in the database
for the researchers. Formalin-fixed, paraffin-embedded tissue samples of the primary tumors
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were retrieved from different Departments of Pathology in Denmark, for central pathology
review and immunohistochemical (IHC) analyses.
Tumor review and IHC analyses
All formalin-fixed, paraffin-embedded tumors blocks of the primary tumor of each patient
were collected and whole slides were stained with Hematoxylin and Eosin. The most represen-
tative tumor block was selected for the analyses. Hematoxylin and Eosin slides were reviewed
by a breast pathologist for morphology and grade (VJ). Grade was scored following the modi-
fied Bloom-Richardson system.
For the IHC analysis, tissue microarrays with 2 cores of 2 mm per tissue block were con-
structed. Tissue microarrays 3μ slices were placed on superfrost+ glass slides, and stained and
scored for ER, PR, HER2, Ki67, CK5/6, CK14, and p63. HER2 2+ tumors were evaluated using
SISH (Silver In Situ Hybridization). Scoring of the IHC staining was performed by a breast
pathologist (VJ). A 10% cut-off was used to define a positive staining for all markers, except
Fig 1. Flow chart of patient identification and selection. Stratified by age at breast cancer diagnosis (50 and >50 years), women with diabetes were
2:1 frequency-matched on year of birth and age at breast cancer diagnosis (both in 10-year categories) to women without diabetes, to select ~300 patients
with tumor tissue available. ǂ Exact numbers <5 cannot be shown according to regulations of Statistics Denmark.
doi:10.1371/journal.pone.0170084.g001
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Ki67: low if14% and high if>14% according to the St Gallen guidelines of 2013 [35], and
HER2: negative if 0/1+ and positive if 2+(SISH confirmed)/3+. Tumors were defined as basal-
like if at least one out of three basal markers (CK14, CK5/6, P63) were positive. We also classi-
fied the tumors using the St Gallen guidelines of 2013 using ER, PR, HER2, and Ki67 [35,36].
Diabetes treatment classification
Diabetes status was determined based on medical diagnosis from the National Patient Register.
Diabetes duration was defined as time from age of diabetes diagnosis till age of breast cancer
diagnosis. Women with diabetes were classified as insulin users if at least 2 prescriptions of
insulin were prescribed cumulatively in the period up to one year prior to breast cancer diag-
nosis. Exposure time was defined as time from age of start of insulin till age of breast cancer
diagnosis. For women treated with other non-insulin antidiabetic drugs, the same method was
used. Women with diabetes treated with insulin only were considered patients with type 1 dia-
betes, if they had a recorded diagnosis of type 1 diabetes (n = 21), or a medical code was miss-
ing but they were under age 30 years at diabetes diagnosis (n = 4). All other women with
diabetes were considered type 2.
Imputation
For women with unknown menopausal status (n = 5), age over 52 years [37] was used as a
proxy for postmenopausal status. Missing values for BMI (n = 51 in women with diabetes,
n = 42 in women without diabetes) were imputed using Multivariate Imputations by Chained
Equations [38] in R studio with a predictive mean matching regression model for each ana-
lyzed dataset, imputing variables with ascending number of missing values; number of imputa-
tions = 10, number of iterations = 25; see (S1 Table). We assumed that data was missing at
random and could be imputed because of correlations with other variables (S2 and S3 Tables).
Variables derived from the DBCG, i.e., age of breast cancer diagnosis, year of breast cancer
diagnosis, menopausal status (for analyses in all women), breast cancer treatment; the elec-
tronic patient files, i.e., smoking, alcohol, height, weight, HbA1C levels; the National Patient
Registry, i.e., diabetes type, diabetes duration, cardiovascular disease, microvascular disease,
income, education; the Danish Register of Medicinal Products Statistics, i.e., diabetes medica-
tion, hormone replacement treatment and oral contraception use; and data on breast cancer
characteristics and clinicopathological subtypes. In the subsequent analyses, we only included
the variables relevant for the prediction of clinicopathological subtype, i.e. age, menopausal
status, smoking, alcohol, BMI, HbA1C, diabetes duration, oral contraception use and hormone
replacement treatment.
Statistical analyses
Patient and breast cancer characteristics at diagnosis were compared between breast cancer
patients with and without diabetes using chi-square tests. Multivariable logistic regression
models were used to estimate the association between diabetes status or insulin treatment with
primary breast cancer clinicopathological subtypes. We constructed separate logistic regres-
sion models for each exposure (diabetes or insulin) to evaluate tumor subtype (various defini-
tions) as model-specific outcomes. Multinomial logistic regression models were used for
tumor subtypes which consisted of>2 categories. We tested for heterogeneity between insulin
and non-insulin users in analysis restricted to diabetes patients only. In the analyses compar-
ing women with and without diabetes, potential covariates were added in a one by one-step-
wise manner; however, none of the covariates changed the beta-estimate for diabetes with
>10% for any of the subtype classifications, except for BMI in the analysis of PR status and
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ER-/PR- in premenopausal women. Nonetheless, we are also showing adjusted models with
breast cancer subtypes for age and BMI, because previous literature has shown associations
between age, BMI and breast cancer subtypes [31]. Models for grade were adjusted for age
only.
Modifications of the associations between diabetes status and breast cancer subtypes by
menopausal status, BMI, and diabetes type were assessed using interactions terms. Although
we found no statistically significant interactions between menopausal status and diabetes sta-
tus (the lowest p-value was 0.07 in the analyses of PR), we show results for pre- and postmeno-
pausal women separately based on previous evidence for different risk profiles [31]. To
exclude potential bias by the inclusions of women with type 1 diabetes we performed a sensi-
tivity analysis excluding women with type 1 diabetes. Moreover, explorative analyses were per-
formed within women with type 1 and type 2 diabetes. SAS Enterprise guide 4.2 for Windows
was used for statistical analyses.
Results
This cross-sectional study consisted of 211 women with diabetes and 101 women without dia-
betes, all diagnosed with breast cancer and with tumor tissue available (Fig 1). Breast cancer
patients with diabetes had a similar distribution of menopausal status (as a result of the age-
stratified selection), but were more often obese (BMI30) (p<0.0001), compared to those
without diabetes (Table 1). The majority of women with diabetes (88.2%) were diagnosed with
type 2 diabetes and the mean diabetes duration was 8.9 years (S3 Table). Twenty-five percent
(n = 53) of the women with diabetes were treated with insulin; including 18 combined with
non-insulin antidiabetic drugs. The non-insulin users were treated with non-insulin antidia-
betic drugs (35%) or diabetes was controlled by diet and exercise only (40%) (S3 Table). The
mean duration of insulin use was 8.4 years (S3 Table). Insulin users (47% type 1 diabetes
women) were more often premenopausal compared to non-insulin users (p = 0.04); and insu-
lin users with premenopausal breast cancer had lower BMI compared to those not treated with
insulin (p = 0.0003) (S4 Table).
Association between diabetes and clinicopathological breast cancer
subtypes
Breast cancer patients with diabetes had a similar distribution of morphology, tumor size, and
number of positive lymph nodes compared to those without diabetes (Table 1); also if stratified
for menopausal status (S5 Table).
Premenopausal breast cancer patients with diabetes had more often PR-negative
(OR = 2.44(95%CI:1.07–5.55), p = 0.03), HER2-negative (OR = 2.84(95%CI:1.11–7.21),
p = 0.03), and basal-like (OR = 3.14(95%CI:1.03–9.60), p = 0.05) tumors than those without
diabetes, with non-statically significant increased frequencies of ER-negative (OR = 2.48(95%
CI:0.95–6.45)) and triple negative (OR = 2.60(95%CI:0.88–7.67) tumors (Table 2 and S6
Table). After adjustment for age and BMI, the associations remained similar in size but less sta-
tistically significant. We found no statistically significant associations between diabetes status
and grade or Ki67, nor using the more refined St. Gallen subtyping (Table 2 and S6 Table). We
found no modification of breast cancer subtype by BMI or diabetes type. Sensitivity analyses,
in which women with type 1 diabetes were excluded, resulted in hazard ratios of the same
direction and similar size (S7 Table). We did not find an association between any of the clini-
copathological breast cancer subtypes and diabetes in postmenopausal women (Table 2). In
analyses including all women, we only found statistically significant more basal-like tumors in
women with diabetes compared to those without (OR = 2.39(95%CI:1.07–5.35), p = 0.03).
Diabetes and Breast Cancer Subtypes
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Table 1. Characteristics of breast cancer patients with and without diabetes.
Women with breast cancer
Diabetes (n = 211) No Diabetes (n = 101) P d
Age, median (IQ range) a, b
 50 years 47.0 (43.0–50.0) 47.0 (43.0–50.0)
> 50 years 67.0 (60.0–75.0) 67.0 (62.0–73.0)
% (n) % (n)
Year of breast cancer diagnoses a
2000–2002 12.8 (27) 6.9 (7)
2003–2004 15.6 (33) 16.8 (17)
2005–2006 17.5 (37) 33.7 (34)
2007–2008 27.5 (58) 18.8 (19)
2009–2010 26.6 (56) 23.8 (24)
Menopausal status b 0.57
Pre 52.1 (110) 48.5 (49)
Post 47.9 (101) 51.5 (52)
BMI in kg/m2 c
Premenopausal women 0.0002
<25 (normal) 30.3 (27) 46.7 (14)
25 (overweight) 24.7 (22) 50.0 (15)
30 (obese) 44.9 (40) <5 (<5) ǂ
Postmenopausal women 0.005
<25 (normal) 22.5 (16) 55.2 (16)
25 (overweight) 38.0 (27) 31.0 (9)
30 (obese) 39.4 (28) <14 (<5) ǂ
Morphology 0.54
Ductal 75.8 (160) 70.3 (71)
Lobular 7.6 (16) 10.9 (11)
Other 16.6 (35) 18.8 (19)
Tumour size in mm
 20 57.8 (122) 57.4 (58) 0.54
21–50 36.5 (77) 39.6 (40)
>50 5.7 (12) <5 (<5) ǂ
Number of positive lymph nodes 0.50
0 50.3 (102) 54.0 (54)
1–3 32.5 (66) 26.0 (26)
>3 17.2 (35) 20.0 (20)
Grade 0.03
Grade 1 20.3 (41) 19.0 (19)
Grade 2 35.6 (72) 51.0 (51)
Grade 3 44.1 (89) 30.0 (30)
ER 0.08
Positive 77.6 (163) 86.1 (87)
Negative 22.4 (47) 13.9 (14)
PR 0.17
Positive 64.4 (136) 72.3 (73)
Negative 35.6 (75) 27.7 (28)
HER2 0.07
Positive 10.5 (22) 17.8 (18)
(Continued )
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Association between insulin treatment and clinicopathological breast
cancer subtypes
Tumor morphology, tumor size and number of positive lymph nodes did not differ between
women with diabetes treated with or without insulin (S4 Table); similar results were found in
analyses stratified for menopausal status (data not shown).
We observed no statistically significant evidence for the development of poor prognosis
tumors among insulin users (Table 3 and S8 Table). Premenopausal women with diabetes not
using insulin were more likely to develop ER-negative (OR = 3.06(95%CI:1.30–7.20), p = 0.01)
and PR-negative (OR = 2.98(95%CI:1.11–8.00), p = 0.03) compared to women without diabe-
tes, while ORs for ER and PR-negative tumors in insulin users compared to women without
diabetes were only slightly increased (Table 3 and S8 Table). We performed explorative analy-
ses separately in type 1 and type 2 insulin-treated premenopausal women with diabetes trying
to understand these differences between insulin and non-insulin users. The associations
between diabetes and tumor subtypes among type 1 diabetes insulin users were more in line
with the findings in the non-insulin users (e.g. poor prognosis tumors), while we observed a
suggestion that type 2 diabetes insulin users had better prognosis tumors (S8 and S9 Tables).
However, overall, there was no evidence for a statistically significant heterogeneity between
insulin and non-insulin users for any of the clinicopathological subtypes in the analyses
restricted to breast cancer patients with diabetes (Table 3). In addition, adjustment for age and
BMI did not materially change the effect estimates or their 95% confidence intervals (S8 and
S10 Tables). In postmenopausal women, we observed no association of insulin, with breast
cancer subtypes (Table 3). We did not have enough power to include subtypes using the more
refined St Gallen criteria in the analyses stratified by menopausal status. In analyses including
all women, we found significantly more basal-like tumors (OR = 2.5(95%CI:1.09–5.74),
p = 0.03) and ER-/PR-negative tumors (OR = 1.99(95%CI:1.00–3.95), p = 0.05) in non-insulin
users compared to women without diabetes.
Discussion
We found no compelling evidence that women with diabetes develop different clinicopatho-
logical subtypes compared to women without diabetes. However, premenopausal breast cancer
patients with diabetes tend to develop breast tumors that do not express hormonal receptors
and basal-like tumors, which are typically associated with poor prognosis. The majority of the
women in our population had type 2 diabetes mellitus, so the results are most applicable for
these patients. We also found no strong evidence that insulin treatment is associated with
Table 1. (Continued)
Women with breast cancer
Diabetes (n = 211) No Diabetes (n = 101) P d
Negative 89.5 (187) 82.2 (83)
a Matching variable,
b at breast cancer diagnosis,
c closest measure prior to breast cancer diagnosis,
d Chi-square test. Missing values are not shown, therefore the sum of the categories does not add up to the total number of patients for BMI, positive lymph
nodes, grade, ER and HER2.
ǂ Exact numbers <5 with percentages cannot be shown according to regulations of Statistics Denmark.
IQ = interquartile range, BMI = Body Mass Index.
doi:10.1371/journal.pone.0170084.t001
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clinicopathological subtypes; though the poor-prognosis tumors were more often occurring in
premenopausal women with diabetes not using insulin and in type 1 diabetes insulin users.
Only a few studies have investigated breast cancer characteristics among women with dia-
betes [20,22,39,40]. Two previous studies stratified the results for menopausal status and they
also found that premenopausal women developed more often tumors that were hormone
receptor negative [22,39], after multivariable adjustment [39]. Overall results were consistent
Table 2. Crude and adjusted odds ratios for breast cancer clinicopathological subtypes of women with diabetes compared to women without dia-
betes in subgroups of menopausal status using (multinomial) logistic regression.
Premenopausal women with breast cancer
Dependent variable Independent variable of exposure
Diabetes vs. No Diabetes Diabetes vs. No Diabetes
crude OR (95% CI) P adjusted OR * (95% CI) P
Grade 2 (vs. grade 1) 0.56 (0.22–1.42) 0.22 0.56 (0.22–1.42) 0.22
Grade 3 (vs. grade 1) 1.02 (0.40–2.61) 0.97 1.08 (0.41–2.86) 0.88
ER- (vs. ER+) 2.48 (0.95–6.45) 0.06 2.32 (0.86–6.31) 0.10
PR- (vs. PR+) 2.44 (1.07–5.55) 0.03 2.18 (0.92–5.17) 0.07
HER2- (vs. HER2+) 2.84 (1.11–7.22) 0.03 2.94 (1.08–8.02) 0.04
High ki67 (vs. low ki67) 1.23 (0.62–2.42) 0.55 1.17 (0.53–2.58) 0.70
Basal-like a (vs. non-basal-like) 3.14 (1.03–9.60) 0.05 3.11 (0.98–9.86) 0.05
ER+/PR- (vs. ER+/PR+) 2.10 (0.55–7.96) 0.28 1.77 (0.43–7.18) 0.42
ER-/PR- (vs. ER+/PR+) 2.67 (1.02–7.00) 0.05 2.46 (0.90–6.75) 0.08
Luminal B-like, HER2- c (vs. luminal A-like b) 1.15 (0.47–2.82) 0.76 1.05 (0.40–2.73) 0.92
HER2+ d (vs. luminal A-like) 0.46 (0.17–1.23) 0.12 0.41 (0.14–1.20) 0.10
Triple-negative e (vs. luminal A-like) 2.60 (0.88–7.67) 0.08 2.21 (0.71–6.69) 0.17
Postmenopausal women with breast cancer
Dependent variable Independent variable of exposure
Diabetes vs. No Diabetes Diabetes vs. No Diabetes
crude OR (95% CI) P adjusted OR * (95% CI) P
Grade 2 (vs. grade 1) 0.80 (0.32–2.04) 0.65 0.80 (0.31–2.03) 0.64
Grade 3 (vs. grade 1) 1.97 (0.72–5.39) 0.19 1.97 (0.72–5.39) 0.19
ER- (vs. ER+) 1.27 (0.52–3.14) 0.60 1.33 (0.52–3.40) 0.55
PR- (vs. PR+) 0.96 (0.48–1.93) 0.92 1.06 (0.51–2.19) 0.88
HER2- (vs. HER2+) 1.15 (0.43–3.13) 0.78 1.20 (0.40–3.59) 0.75
High ki67 (vs. low ki67) 1.11 (0.56–2.22) 0.77 1.06 (0.52–2.18) 0.87
Basal-like a (vs. non-basal-like) 1.62 (0.50–5.29) 0.43 1.73 (0.51–5.91) 0.38
ER+/PR- (vs. ER+/PR+) 0.79 (0.33–1.87) 0.59 0.89 (0.36–2.19) 0.79
ER-/PR- (vs. ER+/PR+) 1.20 (0.48–3.04) 0.69 1.29 (0.49–3.39) 0.60
Luminal B-like, HER2- c (vs. luminal A-like b) 0.65 (0.29–1.44) 0.29 0.58 (0.25–1.35) 0.21
HER2+ d (vs. luminal A-like) 0.79 (0.28–2.26) 0.66 0.88 (0.28–2.71) 0.82
Triple-negative e (vs. luminal A-like) 1.29 (0.41–4.00) 0.66 1.30 (0.40–4.20) 0.67
Logistic regression for tumor subtypes with 2 categories and multinomial logistic regression for tumor subtype with >2 categories as the dependent variable.
a Positive for1 of the basal markers CK56, CK14, and P63,
b ER+, PR+, HER2-, low Ki67,
c ER+, PR-, HER2- with high Ki67,
d ER+ or ER-, PR+ or PR-, HER2+,
e ER-, PR-, HER2-.
* Adjusted for age and BMI (continuous), except for grade, which is adjusted for age only.
OR = Odds Ratio, CI = Confidence Interval.
doi:10.1371/journal.pone.0170084.t002
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with ours, showing more ER-negative, PR-negative and HER2-negative tumors in women
with diabetes, with relative frequencies of 1.5 to 2.5, but most differences were not statistically
significant, except for PR [20,22] and ER, even after adjustment for BMI [40]. A few studies
that reported tumor markers (ER, PR, and some HER2 status) among women with diabetes
[11–13,26,41] compared (breast cancer) mortality or disease-free survival among women with
and without diabetes as their primary objective. Therefore, only crude estimates of associations
between diabetes and tumor subtype were reported and not stratified for menopausal status.
Women included in these studies were mainly postmenopausal and no significant associations
were found between tumor markers and diabetes status.
Studies on the association between diabetes treatment and breast cancer subtype are even
more scarce. No difference in tumor stage and tumor subtype among glargine versus non-glar-
gine users was previously described [42,43]. Studies that compared metformin users to women
with diabetes treated with sulphonylurea or insulin (non-metformin) showed no difference in
ER status [20,44], but sulphonylurea or insulin users presented more PR-negative tumors
(63.0% versus 26.7%, p = 0.041) [44] and more HER-2 positive (29.5% versus 21%, p = 0.002)
[20] than in the metformin-treated subgroup.
Our study was based on the comprehensive biobanks (archival tumor tissue from a ran-
domly selected group of women), and databases available in Denmark, and included medica-
tion history at least five years prior to breast cancer diagnosis from prescription records,
Table 3. Crude and adjusted odds ratios for breast cancer clinicopathological subtypes of women with diabetes treated with or without insulin
compared to women without diabetes in subgroups of menopausal status using (multinomial) logistic regression.
Premenopausal women with breast cancer
Dependent variable Independent variable of exposure
Insulin * vs. No Diabetes No Insulin † vs. No Diabetes Diabetes only
Insulin vs. No Insulin
crude OR (95% CI) P crude OR (95% CI) P P
Grade 2 (vs. grade 1) 0.55 (0.18–1.68) 0.29 0.57 (0.21–1.58) 0.28 0.93
Grade 3 (vs. grade 1) 0.53 (0.16–1.74) 0.30 1.34 (0.49–3.67) 0.57 0.09
ER- (vs. ER+) 1.54 (0.45–5.24) 0.49 2.98 (1.11–8.00) 0.03 0.20
PR- (vs. ER+) 1.37 (0.47–4.00) 0.57 3.06 (1.30–7.20) 0.01 0.08
HER2- (vs. ER+) 8.97 (1.10–73.36) 0.04 2.16 (0.82–5.67) 0.12 0.19
High ki67 (vs. low ki67) 0.80 (0.32–1.96) 0.62 1.48 (0.72–3.05) 0.29 0.15
Postmenopausal women with breast cancer
Dependent variable Independent variable of exposure
Insulin * vs. No Diabetes No Insulin † vs. No Diabetes Diabetes only
Insulin vs. No Insulin
crude OR (95% CI) P crude OR (95% CI) P P
Grade 2 (vs. grade 1) 0.60 (0.12–2.96) 0.53 0.85 (0.32–2.25) 0.75 0.66
Grade 3 (vs. grade 1) 2.05 (0.43–9.78) 0.37 1.95 (0.69–5.55) 0.21 0.95
ER- (vs. ER+) 1.47 (0.39–5.58) 0.57 1.23 (0.38–3.15) 0.66 0.78
PR- (vs. ER+) 1.01 (0.34–3.01) 0.98 0.95 (0.46–1.96) 0.89 0.90
HER2- (vs. ER+) 0.83 (0.19–3.60) 0.80 1.26 (0.44–3.63) 0.67 0.56
High ki67 (vs. low ki67) 0.80 (0.26–2.46) 0.70 1.19 (0.58–2.45) 0.63 0.46
Logistic regression for tumor subtypes with 2 categories and multinomial logistic regression for tumor subtype with >2 categories as the dependent variable.
* Women with diabetes treated with insulin (analogues) regardless the use of concomitant non-insulin antidiabetic drugs,
† women with diabetes treated only with diet and exercise and users of non-insulin antidiabetic drugs only.
OR = Odds Ratio, CI = Confidence Interval.
doi:10.1371/journal.pone.0170084.t003
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resulting in a patient selection minimally affected by survival, selection or ascertainment bias.
Due to oversampling of young breast cancer patients, we could examine the association
between diabetes and clinicopathological subtypes in both pre- and post-menopausal women.
An experienced breast pathologist reviewed all tumor samples and we had complete data on
IHC markers (including basal markers). All IHC stainings were validated and performed in
one center and scored by the same breast pathologist, to prevent inter-laboratory and inter-
observer variability [45,46] and to assure quality of the data. Additionally, data on risk factors
such as BMI were obtained and effect estimates were adjusted for potential confounders and
we followed the STROBE recommendations in reporting scientific research (S11 Table).
Our study was only sufficiently powered (around 80%; likelihood-ratio test with a two-
sided p-value of 0.05) to detect large differences between breast cancer subtypes, e.g. 80% ver-
sus 60% ER-positive tumors, in women with and without diabetes and therefore, subtle differ-
ences may not have been detected. Furthermore, given the design of our study, in which odds
ratios may represent on overestimation of the real risks, validation using prospective cohort
analyses is recommended. Unfortunately, we had insufficient power for separate analyses of
diabetes type 1 and different insulin analogues. We had also limited power to investigate the
duration/dose of insulin exposure and the effect on breast cancer subtype. However, the
majority of insulin users had prescriptions of insulin over several years.
We had no information on whether breast cancer patients were mammography screen-
detected or not. Breast cancer subtype of screen-detected tumors differs from tumors found
outside of screening [47] and there may be a higher non-participation for screening among
postmenopausal women with diabetes compared to women without diabetes [48]. However,
Danish national screening programs started only in 2007 for women aged 50–69 [49]. All sta-
tistically significant differences in our study were found in premenopausal women <52 years,
which were mostly not screened, because the use of opportunistic screening in Denmark is low
[49].
BMI, HbA1C and other risk factors such as alcohol and smoking were collected from the
medical records of patients and were incomplete. However, since we had extensive data on
variables associated with e.g. BMI, we were able to impute missing values using multiple impu-
tations. Although the ratios for observed and imputed BMI were similar, BMI could still be
misclassified for some patients. However, we think that misclassification of BMI is unlikely to
influence our results, since BMI did not affect the association between diabetes and breast can-
cer subtype, except for PR status in premenopausal women. Nevertheless, we have to interpret
both our positive and null results with caution.
There may be several reasons why we found a stronger and significant association between
hormone receptor negative tumors and diabetes in premenopausal compared to postmeno-
pausal women. Differences in levels of BMI-related and reproductive hormones, i.e., factors
related to menopausal status, such as insulin, estrogen and adipokine, may play a role in tumor
subtype formation. However, in contrast to what we have observed in postmenopausal
women, a previous study showed increased estrogen levels in women with diabetes [19], which
would imply that postmenopausal women would more often develop ER-positive tumors.
For the interpretation of the results, it is important to realize that diabetes and BMI are
strongly associated. Women with diabetes are more likely to be obese, and premenopausal
obese women tend to develop hormone receptor negative tumors [50]. Such an association
between BMI and hormone receptor negative breast cancer has not been observed in postmen-
opausal women. Our results on the association between diabetes and breast cancer subtypes
are in line with these findings, even after adjustment for BMI. The same has been reported by
two other studies [39,40], which might indicate that diabetes itself contributes to higher rates
of hormone receptor negative breast cancer in obese women. Our observation that poor
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prognosis tumors are unlikely to occur more often in premenopausal women using insulin, is
in line with the earlier reports that insulin (analogues) do not increase the risk of breast cancer
overall [10]. However, more research is needed for type 1 diabetes.
Diabetes medication depends on the type of diabetes, as well as the severity (insulin depen-
dent, no endogenous insulin versus insulin resistant, high levels of endogenous insulin) and
duration of diabetes. Not much is known about the mechanism, by which insulin treatment
would possibly influence the receptor phenotype of breast cancer. It has been shown that insu-
lin can induce ER and PR expression, which leads to increased binding capacity of ER in
MCF-7 breast cancer cell line [51]. This may suggest that women with diabetes treated with
insulin would develop more ER and PR-positive tumors, which we did not observe. Moreover,
the interpretation and translation of in vivo and in vitro studies to the human setting is difficult
[5].
In summary, our findings suggest that premenopausal women with diabetes tend to develop
triple negative and basal tumors, which are typically associated with poor prognosis. Though
our study had limited power, our results warrant further investigation and future studies
should stratify their analyses by menopausal status.
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